Arbutus Biopharma Corp
corporate_fare Company Profile
Arbutus Biopharma Corp (NASDAQ:ABUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ABUS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ABUS spans 8-K, SC TO-I/A, SC TO-I, 10-Q.
Recent high-impact activity:
- Arbutus Posts $59.1M Q3 Profit on Genevant Dividend, Expands Pfizer/BioNTech Patent Suits
- Arbutus Swings to $59.1M Third-Quarter Profit
- FDA Lifts Clinical Hold on Arbutus's AB-101 Oral PD-L1 Inhibitor IND
- FDA Lifts Clinical Hold on Arbutus's Oral PD-L1 Inhibitor AB-101
- Arbutus Completes $230M Dutch Auction Tender Offer at $5.00/Share, Retiring 23% of Shares
Financial Snapshot
Short Interest & Short Volume
9.14 days to coverFINRA reported short interest of 19,888,395 shares in ABUS as of the October 30, 2026 settlement, a 19.0% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of ABUS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.